These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

341 related articles for article (PubMed ID: 9861017)

  • 1. Overexpression of Mdm2 in mice reveals a p53-independent role for Mdm2 in tumorigenesis.
    Jones SN; Hancock AR; Vogel H; Donehower LA; Bradley A
    Proc Natl Acad Sci U S A; 1998 Dec; 95(26):15608-12. PubMed ID: 9861017
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The tumorigenic potential and cell growth characteristics of p53-deficient cells are equivalent in the presence or absence of Mdm2.
    Jones SN; Sands AT; Hancock AR; Vogel H; Donehower LA; Linke SP; Wahl GM; Bradley A
    Proc Natl Acad Sci U S A; 1996 Nov; 93(24):14106-11. PubMed ID: 8943068
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Loss of one but not two mdm2 null alleles alters the tumour spectrum in p53 null mice.
    McDonnell TJ; Montes de Oca Luna R; Cho S; Amelse LL; Chavez-Reyes A; Lozano G
    J Pathol; 1999 Jul; 188(3):322-8. PubMed ID: 10419603
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oncogenic c-Myc-induced lymphomagenesis is inhibited non-redundantly by the p19Arf-Mdm2-p53 and RP-Mdm2-p53 pathways.
    Meng X; Carlson NR; Dong J; Zhang Y
    Oncogene; 2015 Nov; 34(46):5709-17. PubMed ID: 25823025
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An alternative splice form of Mdm2 induces p53-independent cell growth and tumorigenesis.
    Steinman HA; Burstein E; Lengner C; Gosselin J; Pihan G; Duckett CS; Jones SN
    J Biol Chem; 2004 Feb; 279(6):4877-86. PubMed ID: 14612455
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53.
    Montes de Oca Luna R; Wagner DS; Lozano G
    Nature; 1995 Nov; 378(6553):203-6. PubMed ID: 7477326
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Translational enhancement of mdm2 oncogene expression in human tumor cells containing a stabilized wild-type p53 protein.
    Landers JE; Cassel SL; George DL
    Cancer Res; 1997 Aug; 57(16):3562-8. PubMed ID: 9270029
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeted expression of MDM2 uncouples S phase from mitosis and inhibits mammary gland development independent of p53.
    Lundgren K; Montes de Oca Luna R; McNeill YB; Emerick EP; Spencer B; Barfield CR; Lozano G; Rosenberg MP; Finlay CA
    Genes Dev; 1997 Mar; 11(6):714-25. PubMed ID: 9087426
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bax loss impairs Myc-induced apoptosis and circumvents the selection of p53 mutations during Myc-mediated lymphomagenesis.
    Eischen CM; Roussel MF; Korsmeyer SJ; Cleveland JL
    Mol Cell Biol; 2001 Nov; 21(22):7653-62. PubMed ID: 11604501
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cooperativity of p19ARF, Mdm2, and p53 in murine tumorigenesis.
    Moore L; Venkatachalam S; Vogel H; Watt JC; Wu CL; Steinman H; Jones SN; Donehower LA
    Oncogene; 2003 Oct; 22(49):7831-7. PubMed ID: 14586409
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Decreased Mdm2 expression inhibits tumor development and extends survival independent of Arf and dependent on p53.
    Eischen CM; Boyd K
    PLoS One; 2012; 7(9):e46148. PubMed ID: 23029416
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MDM2 oncogene as a novel target for human cancer therapy.
    Zhang ; Wang H
    Curr Pharm Des; 2000 Mar; 6(4):393-416. PubMed ID: 10788589
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rescue of Mdm4-deficient mice by Mdm2 reveals functional overlap of Mdm2 and Mdm4 in development.
    Steinman HA; Hoover KM; Keeler ML; Sands AT; Jones SN
    Oncogene; 2005 Nov; 24(53):7935-40. PubMed ID: 16027727
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel mouse model of rhabdomyosarcoma underscores the dichotomy of MDM2-ALT1 function in vivo.
    Comiskey DF; Jacob AG; Sanford BL; Montes M; Goodwin AK; Steiner H; Matsa E; Tapia-Santos AS; Bebee TW; Grieves J; La Perle K; Boyaka P; Chandler DS
    Oncogene; 2018 Jan; 37(1):95-106. PubMed ID: 28892044
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The tumor suppressor p53 and the oncoprotein simian virus 40 T antigen bind to overlapping domains on the MDM2 protein.
    Brown DR; Deb S; Muñoz RM; Subler MA; Deb SP
    Mol Cell Biol; 1993 Nov; 13(11):6849-57. PubMed ID: 8413278
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Loss of one allele of ARF rescues Mdm2 haploinsufficiency effects on apoptosis and lymphoma development.
    Eischen CM; Alt JR; Wang P
    Oncogene; 2004 Nov; 23(55):8931-40. PubMed ID: 15467748
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MDM2 overexpression with alteration of the p53 protein and gene status in oral carcinogenesis.
    Li XJ; Murai M; Koyama T; Wang DY; Hashimoto K
    Jpn J Cancer Res; 2000 May; 91(5):492-8. PubMed ID: 10835493
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overexpression of the MDM2 oncogene in leukemia and lymphoma.
    Watanabe T; Ichikawa A; Saito H; Hotta T
    Leuk Lymphoma; 1996 May; 21(5-6):391-7, color plates XVI following 5. PubMed ID: 9172803
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53.
    Jones SN; Roe AE; Donehower LA; Bradley A
    Nature; 1995 Nov; 378(6553):206-8. PubMed ID: 7477327
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-tumor efficacy of a novel antisense anti-MDM2 mixed-backbone oligonucleotide in human colon cancer models: p53-dependent and p53-independent mechanisms.
    Wang H; Nan L; Yu D; Lindsey JR; Agrawal S; Zhang R
    Mol Med; 2002 Apr; 8(4):185-99. PubMed ID: 12149568
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.